| Detailed information |
|---|
| CancerLivER ID | 2107 |
| Biomarker | Combination of S100A9 and GRN |
| Biomarker Name/Symbol (given in Publication) | Combination of S100A9 and GRN |
| Biomolecule | Others |
| Subject | Human |
| Degree of Validity | Potential combinatorial biomarkers for early detection of HCC and associated with survival; but not validated on independent dataset |
| Experimental Condition | Normal vs HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCC patients |
| Level of significance | p < 0.001 |
| Source | Urine |
| PMID | 26675302 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | MAPK signaling pathway |
| Cohort | Urine samples collected from 44 patients who were diagnosed as cases of HCC incidence and never underwent cholecystectomy as the disease group;44 patients diagnosed with non-HCC incidence but underwent cholecystectomy for urine collection as the normal control |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2015 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |